BioCentury | Jun 17, 2020

Crossovers pile into new rounds for C4, 4D Molecular

Protein degradation company C4 and gene therapy play 4D Molecular each raised venture rounds that included crossover investors, suggesting each company could soon join an IPO queue that has burgeoned in recent weeks. 4D had...
Items per page:
1 - 1 of 1